XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Income Statement [Abstract]        
Revenue $ 6,345 $ 5,069 $ 11,267 $ 13,764
Cost of revenue 4,736 3,681 8,799 9,943
Gross profit 1,609 1,388 2,468 3,821
Operating expenses        
Research and development 665 559 1,410 1,161
Selling and shipping 426 428 845 847
General and administrative 1,416 1,360 2,739 2,960
Loss on disposition of Tantaline 162 162
Impairment charge 111 111
Total operating expenses 2,507 2,620 4,994 5,241
Operating loss (898) (1,232) (2,526) (1,420)
Other income (expense):        
Interest income 145 107 302 227
Interest expense (4) (6) (10) (12)
Foreign exchange income 15 43
Other income (expense) (4) 13 1 20
Total other income, net 137 129 293 278
Loss before income tax (761) (1,103) (2,233) (1,142)
Income tax expense 10 11
Net loss $ (761) $ (1,113) $ (2,233) $ (1,153)
Loss per common share - basic $ (0.11) $ (0.16) $ (0.33) $ (0.17)
Loss per common share - diluted $ (0.11) $ (0.16) $ (0.33) $ (0.17)
Weighted average common shares        
Basic 6,816,956 6,778,754 6,813,127 6,776,035
Diluted 6,816,956 6,778,754 6,813,127 6,776,035